Davita Inc vs NEOS S&P 500 High Income ETF — how do they compare? Davita Inc trades at $232 (market cap $15.12B), while NEOS S&P 500 High Income ETF trades at $53.7. Which is the better fit depends on your goals.
| DVA | SPYI | |
|---|---|---|
Market Cap | $15.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $235.71 | $54.07 |
52-Week Low | $103.87 | $47.98 |
Enterprise Value | $27.67B | — |
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →